Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients

MeSH terms

• Adenosine / analogs & derivatives*
• Adenosine Monophosphate* / administration & dosage
• Adenosine Monophosphate* / analogs & derivatives*
• Adenosine Monophosphate* / therapeutic use
• Aged
• Alanine* / administration & dosage
• Alanine* / analogs & derivatives*
• Alanine* / therapeutic use
• Antibodies, Monoclonal, Humanized / administration & dosage
• Antibodies, Monoclonal, Humanized / therapeutic use
• Antiviral Agents* / administration & dosage
• Antiviral Agents* / therapeutic use
• COVID-19
• COVID-19 Drug Treatment*
• Drug Therapy, Combination*
• Female
• Humans
• Immunocompromised Host*
• Male
• Middle Aged
• SARS-CoV-2* / drug effects
• Treatment Outcome